Translational development of BAFF-R-specific chimeric antigen receptor T-cell therapy targeting B-cell lymphoid malignancies. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for non-responsive or relapsing hematological malignancies, providing an intensive, personalized form of immunotherapy. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results